The TGA has extended use of pembrolizumab (Keytruda) to include locally advanced or metastatic urothelial cancer in patients either not eligible for cisplatin-containing therapies or those who have previously received platinum-containing chemotherapy. As reported previously in the limbic here, KEYNOTE-045 found an overall survival benefit in patients treated with pembrolizumab compared to second line chemotherapy ...
Checkpoint inhibition option for bladder cancer patients
By Mardi Chapman
18 Jan 2018